Themis Medicare Ltd - Stock Valuation and Financial Performance

BSE: 530199 | NSE: THEMISMED | Pharmaceuticals & Drugs | Small Cap

Themis Medicare Share Price

262.20 3.70 1.43%
as on 31-Oct'24 16:01

DeciZen - make an informed investing decision on Themis Medicare

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Themis Medicare stock performance -

mw4me loader
P/E Ratio (SA):
66.00
Market Cap:
2,414.7 Cr.
52-wk low:
142.6
52-wk high:
304.3

Is Themis Medicare Ltd an attractive stock to invest in?

1. Is Themis Medicare Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Themis Medicare Ltd is a average quality company.

2. Is Themis Medicare Ltd undervalued or overvalued?

The key valuation ratios of Themis Medicare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Themis Medicare Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Themis Medicare Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Themis Medicare:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Themis Medicare Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 10%16.8%14.7%9.3%-1.2%12.8%17%31.3%19.7%11.4%-
Value Creation
Index
-0.30.20.1-0.3-1.1-0.10.21.20.4-0.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 167203217210184202231395354382386
Sales YoY Gr.-21.6%6.8%-3.3%-12.1%9.5%14.4%71.1%-10.2%7.7%-
Adj EPS 0.31.81.71-1.41.72.96.64.52.64
YoY Gr.-532.1%-6.2%-38%-239.8%NA65.7%130.5%-32.1%-42.6%-
BVPS (₹) 5.87.615.416.915.617.320.226.430.632.735.3
Adj Net
Profit
2.315.1159.4-13.315.826.260.54123.637
Cash Flow from Ops. 1118.7-1.57.9110.35734.416.122-
Debt/CF from Ops. 105.1-54.610.27.5299.21.52.35.74.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.6%15.7%18.3%7.7%
Adj EPS 27.9%NA-3.5%-42.6%
BVPS21.3%16.1%17.5%6.9%
Share Price 32.1% 56.9% 45.6% 74.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
4.826.614.66.3-8.910.415.228.215.68.111.7
Op. Profit
Mgn %
6.815.515.112.11.417.721.624.21913.516.5
Net Profit
Mgn %
1.47.46.94.5-7.27.811.415.311.66.29.5
Debt to
Equity
2.21.50.60.50.60.60.50.30.30.30
Working Cap
Days
245194183225291302276176250272121
Cash Conv.
Cycle
4546761161711811669514416861

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 18.29%

Sales growth is good in last 4 quarters at 25.87%

Return on Equity has declined versus last 3 years average to 11.70%

Net Profit has been subdued in last 3 years -3.51%

Latest Financials - Themis Medicare Ltd.

Standalone Consolidated
TTM EPS (₹) 4 5.8
TTM Sales (₹ Cr.) 386 420
BVPS (₹.) 35.3 44.8
Reserves (₹ Cr.) 316 403
P/BV 7.42 5.86
PE 66.00 45.57
From the Market
52 Week Low / High (₹) 142.60 / 304.30
All Time Low / High (₹) 1.20 / 304.30
Market Cap (₹ Cr.) 2,415
Equity (₹ Cr.) 9.2
Face Value (₹) 1
Industry PE 46.8

Management X-Ray of Themis Medicare:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *23.5123.5123.5123.5123.5123.512.432.432.432.43
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Themis Medicare

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales167203217210184202231395354382
Operating Expenses 156171184184182166181299287330
Manufacturing Costs30424136323533524955
Material Costs65625658595267131101115
Employee Cost 29324045464440526682
Other Costs 32354846453441647177
Operating Profit 1131322533650966752
Operating Profit Margin (%) 6.5%15.5%14.9%12.0%1.4%17.7%21.6%24.2%19.0%13.5%
Other Income 123343347125
Interest 141212121213139109
Depreciation 777788991012
Exceptional Items 0000000000
Profit Before Tax 215169-151832845935
Tax 0-120-226221610
Profit After Tax 215159-131627624325
PAT Margin (%) 1.2%7.4%6.8%4.4%-6.9%7.9%11.5%15.6%12.2%6.5%
Adjusted EPS (₹)0.21.81.61.0-1.41.72.96.74.72.7
Dividend Payout Ratio (%)0%0%0%0%0%10%15%7%11%19%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 4964140155143159185243282301
Share Capital 8999999999
Reserves 4056130146134150176234273292
Minority Interest0000000000
Debt97826675768879677774
Long Term Debt4430121191222242827
Short Term Debt54525364677757434947
Trade Payables58333231353031324047
Others Liabilities 20413626394543566777
Total Liabilities 225220273288293322338398467499

Fixed Assets

Gross Block151156131141146147172192221239
Accumulated Depreciation5967715233139485971
Net Fixed Assets9289124126123116133144162168
CWIP 3592282333
Investments 11111211111111111111
Inventories48454850535458616971
Trade Receivables404048697310378101145178
Cash Equivalents 68973525261919
Others Assets25212323262431525749
Total Assets 225220273288293322338398467499

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 1119-2811057341622
PBT 1627169-151832845935
Adjustment 661717191817111417
Changes in Working Capital 3-2-35-197-368-43-40-21
Tax Paid 0101000-18-16-9
Cash Flow From Investing Activity -2-4-40-4-5-16-16-24-16
Capex -2-6-5-3-6-6-18-21-29-18
Net Investments 00-11000100
Others 1222202452
Cash Flow From Financing Activity -15-135-9-107-26-180-9
Net Proceeds from Shares 00255000000
Net Proceeds from Borrowing -7-10-13-13-38125-2
Interest Paid 00-11-11-10-11-11-7-8-8
Dividend Paid 000000-2-4-5-5
Others -9-3410310-14-985
Net Cash Flow -620-1-32161-8-3
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)4.226.6214.516.3-8.5110.5515.4728.7216.498.49
ROCE (%)9.9716.8314.749.25-1.1812.7716.9831.2719.6811.43
Asset Turnover Ratio0.740.930.920.750.630.660.71.070.820.79
PAT to CFO Conversion(x)5.51.27-0.130.89N/A02.110.550.370.88
Working Capital Days
Receivable Days79717110114115914383127155
Inventory Days1068276841029789556767
Payable Days31726721019620222716587131138

Themis Medicare Ltd Stock News

Themis Medicare Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Themis Medicare on 31-Oct-2024 16:01 is ₹262.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Oct-2024 16:01 the market cap of Themis Medicare stood at ₹2,414.7.
The latest P/E ratio of Themis Medicare as of 31-Oct-2024 16:01 is 66.00.
The latest P/B ratio of Themis Medicare as of 31-Oct-2024 16:01 is 7.42.
The 52-week high of Themis Medicare is ₹304.3 and the 52-week low is ₹142.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Themis Medicare is ₹386.0 ( Cr.) .

About Themis Medicare Ltd

Themis Medicare (TML) incorporated in 1969, is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs) and Formulations. Erstwhile known as Themis Chemical the company is promoted by Mr. Shantibhai D. Patel. It is joint venture with Gedeon Richter, Hungary.

Headquartered in Mumbai, the company has four manufacturing facilities located at Vapi (Gujarat), Hyderabad (Andhra Pradesh), and Haridwar (Uttaranchal).

The company is backed by strong marketing workforce of 500 people with network of over 2000 stockists. The company has pan-India presence; it also has presence in 40 countries that include international markets namely Europe, Americas and Australasia.

Company has an in-house R&D facility that focuses on development of new chemical, new and efficient processes for production of API and intermediates, fermentation technology and New Drug Delivery Systems.

Themis Medicare is also engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab., Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.

Products

Active Pharmaceutical Ingredients- The Company is manufactures APIs that caters to therapeutic segment such as antituberculosis, antimalarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition. Company manufactures products namely Simvastatin, Lovastatin, Propofol, Ethambutol, Di-methyl Isosorbide, Artesunate, Lumefenterine, Arteether are among others.

Formulations- The company also formulations that caters to therapeutic segment. It has produced products such as Themibutol, Tetracox, Tricox, Ticinex, Ticin are among others.

Milestones

1969- Themis Chemicals was incorporated in joint venture with GEDEON Richter, Hungary.

1971- Themis Chemicals became first company in India and second company in the world to manufacture Vitamin B12 by non-sterile fermentation process.

1976- Themis Chemicals became first company in India and second company in the world to manufacture Ethambutol Dihydrochloride.

1985- RIFAMPICIN was produced for first time in India by Themis Chemicals.

1990- Company developed and manufactured HEMOLOK.

1991-92 Besides Schering Plough of USA, company was only one to manufactures SISOMICIN. Company developed and manufactured ANABLOKTM – an anaesthetic.

1993- It was only private sector company to produce GENTAMICIN in India

1995- For the first time in the world the company produces FUMAGILLIN– a unique veterinary productThemis Chemicals is listed on the Bombay Stock Exchange.

1996- The company became first in India and third in the world to produce LOVASTATIN.

1997- Company received award from Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR).

1998- Company developed Simvastatin for the first time in Asia.

1999- Company launched E MALTM – Alpha Beta Arteether and it also received award from Ministry of Science and Technology’s Department of Scientific and Industrial Research (DSIR) for the same.

2001- Company was rechristened as Themis Medicare

2002- The company for first time in India developed SEPGARDTM – a unique wound healing agent.

2003- For first time in the world, company developed CLEOFOLTM- a Lipid free Clear Propofol Injection. In the same year it also introduced the first COX-2 INJECTION in the world.

2004- Artemis Biotech was merged with Themis Medicare. The company forms its second joint venture with Gedeon Richter of Hungary to set up 100% export oriented unit under the name Richter Themis Medicare (INDIA). The same year the company commissions a new facility at Hyderabad.

2006- Company starts operations of its manufacturing unit located at Haridwar. Company develops and introduces Nimesulide Injection. Company launches THEMISEALTM- a stops bleeding gel and forays in European market. Company started cultivation of Artemisia annua and extraction of Artemisinin.

2007- For first time in the world, the company introduced Aceclofenac Injection.

2010 - Themis Medicare launched a combination of Lidocaine & Prilocaine in 'Spray' form under the brand name ""Lovelong""
2011 - Themis Medicare have introduced for the First Time in the Country a 'calcium' preparation with fruitygummies for paediatric use under the brand name "THEMIBEAR".
The Company have introduced for the First Time in the country a ""Multivitamin"" for Paediatric use under the brand name "THEMIBEAR"
2013 - Introduction of oil free Emal (Alpha beta arteether injection) in ampoules, and PFS  (Pre-Filled Syringe)
Break through development of Diclofenac 75 mg / ml injection using patented technology and assigned exclusive marketing rights to Novartis India Limited under their flagship brand - Voveran 75 mg / ml Injection
Long term partnership signed with Novartis India Limited for exclusive marketing rights of Diclofenac TPM Gel (Voveran TPM Gel) for India

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.